Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 2017; 31: 1391–1397.
Brunning RD, Orazi A, Germing U, Le Beau MM, Porwitt A, Baumann J et al. Myelodysplastic syndromes. In: Swerdlow S, Campos E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, World Health Organization: Lyon, France, 2008, pp 87–107.
Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007; 127: 197–205.
Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014; 28: 185–189.
Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2340–2347.
Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014; 14: 401–410.
Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 2015; 8: 45.
Bejar R, Papaemmanuil E, Haferlach T, Garcia-Manero G, Maciejewski JP, Sekeres M et al. TP53 mutation status divides MDS patients with complex karyotypes into distinct prognostic risk groups: analysis of combined datasets from the International Working Group for MDS-molecular prognostic committee. Blood 2014; 124: 532.
The authors declare no conflict of interest.
About this article
Cite this article
Calvo, X., Florensa, L. & Arenillas, L. Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?. Leukemia 31, 2538–2539 (2017) doi:10.1038/leu.2017.237